Lack of therapeutic efficacy of an antibody to α4β7 in SIVmac251-infected rhesus macaques

P Abbink, NB Mercado, JP Nkolola, RL Peterson… - Science, 2019 - science.org
P Abbink, NB Mercado, JP Nkolola, RL Peterson, H Tuyishime, K McMahan, ET Moseley…
Science, 2019science.org
Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after
discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent
study reported that administration of an antibody against α4β7 induced durable virologic
control after ART discontinuation in 100% of rhesus macaques infected with an attenuated
strain of simian immunodeficiency virus (SIV) containing a stop codon in nef. We performed
similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In …
Sustained virologic control of human immunodeficiency virus type 1 (HIV-1) infection after discontinuation of antiretroviral therapy (ART) is a major goal of the HIV-1 cure field. A recent study reported that administration of an antibody against α4β7 induced durable virologic control after ART discontinuation in 100% of rhesus macaques infected with an attenuated strain of simian immunodeficiency virus (SIV) containing a stop codon in nef. We performed similar studies in 50 rhesus macaques infected with wild-type, pathogenic SIVmac251. In animals that initiated ART during either acute or chronic infection, anti-α4β7 antibody infusion had no detectable effect on the viral reservoir or viral rebound after ART discontinuation. These data demonstrate that anti-α4β7 antibody administration did not provide therapeutic efficacy in the model of pathogenic SIVmac251 infection of rhesus macaques.
AAAS